Methotrexat Kelix Bio (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for producing tetrahydrofolate. This interruption reduces the synthesis of DNA, RNA and proteins, particularly affecting rapidly dividing cells and activated immune cells, thereby providing antineoplastic and immunosuppressive effects.

The dosage of Methotrexat Kelix Bio is individualized by the treating physician based on the specific indication, patient characteristics, renal and hepatic function, and response to therapy. Only a qualified healthcare professional should determine the appropriate regimen.

Methotrexat Kelix Bio is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because of a high risk of fetal harm. It is also not recommended during breastfeeding, as it can be excreted in milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Methotrexat Kelix Bio is a methotrexate‑based product, sharing the same mechanism as other folate antagonists such as pemetrexed. Compared with newer agents, methotrexate has a long‑standing safety profile, extensive clinical experience, and is available in multiple routes of administration, making it a versatile option for both rheumatologic and oncologic indications.

Methotrexat Kelix Bio should be stored at 2‑8 °C, protected from light, and kept in its original packaging to maintain stability. Do not freeze or shake the product. If a temporary temperature excursion occurs, follow the supplier’s guidance before use.

The product is supplied for parenteral use and can be given by intramuscular, intrathecal, or intravenous injection, depending on the clinical indication and prescribing information. Administration should be performed by qualified healthcare personnel using aseptic technique.

Serious risks include severe liver toxicity, pulmonary fibrosis, life‑threatening bone‑marrow suppression, acute renal failure, and severe cutaneous reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for signs of organ dysfunction and educated to report any concerning symptoms promptly.

Methotrexat Kelix Bio is contraindicated in pregnant women, individuals with severe renal or hepatic impairment, active infections, known hypersensitivity to methotrexate, and patients receiving live vaccines. It should also be avoided in patients with uncontrolled immunodeficiency conditions.